Shares of Viking Therapeutics, Inc. (NASDAQ:VKTX – Get Free Report) have been assigned a consensus rating of “Buy” from the ...

Scheduled for 13 weeks, the trial will assess the therapy’s safety, tolerability, and efficacy in weight loss.

Some of the best possible returns for investors come by not going after megacaps, but instead pursuing stocks that have more ...

Viking Therapeutics (VKTX) has received a new Buy rating, initiated by Stifel Nicolaus analyst, Annabel Samimy.Stay Ahead of the ...

In a rare move, the FDA recommended a minimum of 5% weight-loss for drug developers seeking to establish the efficacy of ...

Viking Therapeutics (VKTX) announced the initiation of a Phase 2 clinical trial of the oral tablet formulation of VK2735, the company’s dual ...

Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced the ...

The U.S. FDA has released a new draft guidance for drugmakers to aid them in developing new treatments for obesity. The new ...

The Green Bay Packers and Minnesota Vikings play Sunday, Dec. 29, at the Vikings' U.S. Bank Stadium in a game on the NFL Week 17 schedule. Which team will win the NFL Week 17 game? Check out these ...

Viking Therapeutics, Inc. (VKTX) closed at $42.53 in the latest trading session, marking a -0.84% move from the prior day. The stock fell short of the S&P 500, which registered a gain of 0.55% for the ...

Seeking Alpha analyst Terry Chrisomalis regards Viking Therapeutics as the most attractive M&A candidate in 2025, bolstered ...

JPMorgan highlights valuation resets for Viking and Structure Therapeutics, citing opportunities in T2D/obesity and competitive clinical data insights.